Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690

BMC Medical Research Methodology

Haitao Chu²  Ming-Hui Chen³  Joseph G Ibrahim¹ 

[1] Department of Biostatistics, University of North Carolina, McGavran Greenberg Hall, CB#7420, Chapel Hill, NC, 27599, USA;Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA;Department of Statistics, University of Connecticut, Storrs, CT, USA

关键词: Posterior distribution;    Prior distribution;    Historical data;    Cure rate model;   

Others  :  1126433
DOI  :  10.1186/1471-2288-12-183

 received in 2012-08-10, accepted in 2012-11-06,  发布年份 2012

【 摘 要 】

Background

E1684 was the pivotal adjuvant melanoma trial for establishment of high-dose interferon (IFN) as effective therapy of high-risk melanoma patients. E1690 was an intriguing effort to corroborate E1684, and the differences between the outcomes of these trials have embroiled the field in controversy over the past several years. The analyses of E1684 and E1690 were carried out separately when the results were published, and there were no further analyses trying to perform a single analysis of the combined trials.

Method

In this paper, we consider such a joint analysis by carrying out a Bayesian analysis of these two trials, thus providing us with a consistent and coherent methodology for combining the results from these two trials.

Results

The Bayesian analysis using power priors provided a more coherent flexible and potentially more accurate analysis than a separate analysis of these data or a frequentist analysis of these data. The methodology provides a consistent framework for carrying out a single unified analysis by combining data from two or more studies.

Conclusions

Such Bayesian analyses can be crucial in situations where the results from two theoretically identical trials yield somewhat conflicting or inconsistent results.

【 授权许可】

   
2012 Ibrahim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Berry D, Wathen JK, Newell M: Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clinical Trials 2009, 6(1):28-41.
• [2]Berry SM, Carlin BP, Lee J, Muller P: Bayesian adaptive methods for clinical trials. Boca Raton, FL: Chapman & Hall/CRC; 2010.
• [3]Gelman A, Carlin JB, Stern HS, Rubin DB: Bayesian data analysis. 2nd edition. Boca Raton, FL: Chapman & Hall/CRC; 2004.
• [4]Carlin BP, Louis TA: Bayesian methods for data analysis. 3rd edition. Boca Raton, FL: Chapman & Hall/CRC; 2008.
• [5]Ibrahim JG, Chen MH, Sinha D: Bayesian survival analysis. New York: Springer; 2001.
• [6]Ibrahim JG, Chen MH: Power prior distributions for regression models. Stat Sci 2000, 15(1):46-60.
• [7]Chen MH, Harrington DP, Ibrahim JG: Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group trial E1690. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2002, 51(2):135-150.
• [8]Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1):7-17.
• [9]Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al.: High- and Low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18(12):2444-2458.
• [10]Ewell M, Ibrahim JG: The large sample distribution of the weighted log rank statistic under general local alternatives. Lifetime Data Anal 1997, 3:5-12.
• [11]Chen MH, Ibrahim JG, Sinha D: A new Bayesian model for survival data with a surviving fraction. J Am Statist Assoc 1999, 94:909-919.
• [12]Cho H, Ibrahim JG, Sinha D, Shu H: Bayesian case influence diagnostics for survival models. Biometrics 2009, 65:116-124.